Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06116916




Registration number
NCT06116916
Ethics application status
Date submitted
31/10/2023
Date registered
3/11/2023
Date last updated
3/06/2024

Titles & IDs
Public title
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Scientific title
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema
Secondary ID [1] 0 0
4951-003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetic Macular Edema (DME) 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - KHK4951
Treatment: Drugs - Aflibercept Injection

Experimental: Arm A - KHK4951 High dose

Experimental: Arm B - KHK4951 Middle dose

Experimental: Arm C - KHK4951 Low dose


Treatment: Drugs: KHK4951
KHK4951 eye drop for 36 weeks until end of the trial

Treatment: Drugs: Aflibercept Injection
Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline
Timepoint [1] 0 0
For 36 weeks until the end of the trial
Secondary outcome [1] 0 0
The number of aflibercept IVT
Timepoint [1] 0 0
For 36 weeks until the end of the trial
Secondary outcome [2] 0 0
Change from baseline in SHRM as measured by SD-OCT
Timepoint [2] 0 0
36 Weeks
Secondary outcome [3] 0 0
Change from baseline in retinal morphology as measured by SD-OCT
Timepoint [3] 0 0
36 Weeks
Secondary outcome [4] 0 0
Change from baseline in leakage as measured by FA
Timepoint [4] 0 0
36 Weeks

Eligibility
Key inclusion criteria
- Voluntary written informed consent to participate in the study

- BCVA ETDRS letter score of 73 letters to 35 letters as measured by the ETDRS visual
acuity chart in the study eye at screening

- 500 µm = CST = 325 µm in the study eye at screening

- HbA1c = 11% at screening
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any signs of proliferative diabetic retinopathy in the study eye

- History of rubeosis in the study eye

- Uncontrolled glaucoma in the study eye

- Aphakia or pseudophakia with AC-IOL in the study eye

- Active intraocular inflammation in the study eye

- Any current ocular condition for which visual acuity loss would not improve from
resolution of macular edema in the study eye

- History of rhegmatogenous retinal detachment in the study eye

- Any current or history of ocular disease other than DME that may confound assessment
of the macula or affect central vision in the study eye

- History of the following therapies in the study eye

- History of vitrectomy surgery, submacular surgery, or other surgical intervention
for DME

- Previous use of periocular or intraocular (sub-Tenon or IVT) corticosteroids

- Previous intraocular device implantation except PC-IOL

- Previous laser (any type) to the macular area

- Previous panretinal photocoagulation treatment

- Previous treatment with any IVT anti-VEGF drugs

- Previous use of Ozurdex® or Iluvien® implant

- Any current or history of endophthalmitis in either eye

- History of idiopathic or autoimmune-associated uveitis in either eye

- Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
eye

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/01/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2025
Actual
Sample size
Target
150
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC
Recruitment hospital [1] 0 0
Eye Clinic Albury Wodonga - Albury
Recruitment hospital [2] 0 0
South West Retina - Liverpool
Recruitment hospital [3] 0 0
Marsden Eye Specialists - Parramatta
Recruitment hospital [4] 0 0
Strathfield Retina Clinic - Strathfield
Recruitment hospital [5] 0 0
Sydney Eye Hospital - Sydney
Recruitment hospital [6] 0 0
Sydney Retina Clinic & Day Surgery - Sydney
Recruitment hospital [7] 0 0
Adelaide Eye and Retina Centre - Adelaide
Recruitment hospital [8] 0 0
Hobart Eye Surgeons - Hobart
Recruitment hospital [9] 0 0
Centre for Eye Research Australia - East Melbourne
Recruitment postcode(s) [1] 0 0
02640 - Albury
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
02150 - Parramatta
Recruitment postcode(s) [4] 0 0
2135 - Strathfield
Recruitment postcode(s) [5] 0 0
2000 - Sydney
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
7008 - Hobart
Recruitment postcode(s) [8] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Nevada
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
New Mexico
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Oklahoma
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Vermont
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
Japan
State/province [18] 0 0
Aiti-ken
Country [19] 0 0
Japan
State/province [19] 0 0
Aiti
Country [20] 0 0
Japan
State/province [20] 0 0
Chiba
Country [21] 0 0
Japan
State/province [21] 0 0
Fukuoka
Country [22] 0 0
Japan
State/province [22] 0 0
Fukushima
Country [23] 0 0
Japan
State/province [23] 0 0
Hokkaidô [Hokkaido]
Country [24] 0 0
Japan
State/province [24] 0 0
Hyôgo
Country [25] 0 0
Japan
State/province [25] 0 0
Ibaraki
Country [26] 0 0
Japan
State/province [26] 0 0
Kagawa
Country [27] 0 0
Japan
State/province [27] 0 0
Nagano
Country [28] 0 0
Japan
State/province [28] 0 0
Nara
Country [29] 0 0
Japan
State/province [29] 0 0
Osaka
Country [30] 0 0
Japan
State/province [30] 0 0
Shizuoka
Country [31] 0 0
Japan
State/province [31] 0 0
Tochigi
Country [32] 0 0
Japan
State/province [32] 0 0
Tokyo
Country [33] 0 0
Japan
State/province [33] 0 0
Kyoto
Country [34] 0 0
Japan
State/province [34] 0 0
Saitama
Country [35] 0 0
Japan
State/province [35] 0 0
Ôsaka
Country [36] 0 0
Korea, Republic of
State/province [36] 0 0
Busan Gwang'yeogsi
Country [37] 0 0
Korea, Republic of
State/province [37] 0 0
Daegu Gwang'yeogsi
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Gyeonggido
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Incheon Gwang'yeogsi
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Seoul Teugbyeolsi
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Seoul

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Kyowa Kirin, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients
with DME.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06116916
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sotaro Takigawa
Address 0 0
Kyowa Kirin Co., Ltd.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Kyowa Kirin, Inc.
Address 0 0
Country 0 0
Phone 0 0
+1-609-919-1100
Fax 0 0
Email 0 0
kkd.clintrial.82@kyowakirin.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06116916